Neurology: 

The solvent-free and concentrated CsA product is administered as an intranasal spray and it will reach central nervous system because of the stable and inert PEGylated lipid nanoparticles. By these means it is conveniently applicable to treat chronic neurodegenerative diseases with a neuroinflammatory pathology.

Ophthalmology: 

The clear and solvent-free CsA product is administered as an eye drop and can also reach the back of the eye because of the stable and inert PEGylated lipid nanoparticles. The product has the potential to target several inflammatory eye diseases.

Dermatology: 

The solvent-free CsA product is applied as spray and can target different dermatology indications. This liquid product is ideal for parts of the body where applying a cream is inconvenient and/or irritated parts of the body where friction or stinging solvents are not preferred.

Pulmonology: 

The solvent-free CsA product is administrated by means of a commercially available inhaler and can target pulmonology indications, including COVID-19. Through the inhaler, the lipid nanoparticles carrying the therapeutic can be delivered directly into the smaller airways of the lungs.